FDA Grants R-Tech Ueno IND Approval for Dry Eye Treatment

R-Tech Ueno, Japanese pharmaceutical company, has filed for and received FDA IND approval to begin Phase I and II clinical trials of its severe dry eye treatment, RU -101.

Advertisement

Ophthalmic solution RU-101 contains the serum component albumin, which has shown to aid in the production of tears.

R-Tech Ueno hopes to gain marketing approval for the treatment soon.

More Articles on Ophthalmology:
Pharm, Olam, InSite Vision Complete Phase 3 Clinical Study
Study Finds 65% of Liver Transplant Patients Develop AMD
Glaucoma Management Lens to be Presented at ARVO 2013

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.